The title compound, (E)-4-(3-oxo-3-((4-(N-(pyrimidin-2-yl)sulfamoyl)-phenyl)ami- no)prop-1-en-1-yl)-1,2-phenylene diacetate dimethanol, was synthesized by the reaction of caffeic acid with sulfadiazine and characterized by FT-IR, 1 H-NMR spectroscopy, ESI-MS and X-ray single-crystal diffraction. It crystallizes in triclinic, space group P1 with a=10.302(7), b=11.621(8), c=12.107(8) , α=100.904(9), β=102.624(8), γ=95.501(9)o, V=1374.5(15) 3 , Z=2 , F(000)=588, Dc=1.354 Mg/m3 , Mr=560.57, μ=0.176 mm-1 , λ=0.71073 , the final R=0.0666 and wR=0.1950 for 4774 observed reflections with I > 2σ(I).
The title compound, (E)-N,N′-dicyclohexyl-1-(3-(3,4-dihydroxyphenyl)acryloyl)- urea (DDA), has been synthesized and characterized by FT-IR and 1H-NMR spectroscopy, ESI- MS, and X-ray single-crystal diffraction. Its crystallizes in monoclinic, space group C2/c with a = 20.483(12), b = 11.153(6), c = 21.134(12) , β = 117.098(7), V = 4298(4) 3, Z = 8, F(000) = 1664, Dc = 1.195 Mg/m3, Mr = 386.48, μ= 0.082 mm-1, the final R = 0.0474 and wR = 0.1370 for 4853 observed reflections with I > 2σ(I).
